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Human Papillomavirus Vaccination Series Initiation
and Completion, 2008–2009
WHAT’S KNOWN ON THIS SUBJECT: Routine human
papillomavirus (HPV) vaccination is recommended for girls 11 or
12 years of age (catch-up vaccination through the age of 26
years). Vaccine coverage rates are low but increasing.
WHAT THIS STUDY ADDS: This report describes associations
between sociodemographic characteristics and HPV vaccination
series initiation and completion, information useful for targeted
public health interventions to increase adolescent coverage
rates. It is the first study to use a national sample with provider-
reported vaccination data.
abstract
OBJECTIVE: The goal was to describe factors associated with human
papillomavirus (HPV) vaccination series initiation (1 dose) and com-
pletion (3 doses) and parents’ intent to have their daughters
vaccinated.
METHODS: Data from the 2008 and 2009 National Immunization Survey-
Teen were analyzed to estimate HPV vaccination coverage among girls
13 to 17 years of age (N  18 228) and to examine associations of
vaccination coverage with demographic characteristics.
RESULTS: Overall, 40.5% of girls had received 1 HPV vaccine dose,
and 53.3% of those girls completed the series. Factors independently
associated with vaccination initiation included older age, having an 11-
to 12-year preventive visit, insurance status, mother’s age and marital
status, not receiving all vaccines at public facilities, and provider rec-
ommendation, which was the factor most strongly associated with
initiation (prevalence ratio: 2.6 [95% confidence interval: 2.4–2.9]).
Compared with white girls (60.4%), black (46.0%) and Hispanic (40.3%)
girls were less likely to complete the series. Lack of knowledge of the
vaccine (19.4%), vaccinationwas not needed (18.8%), the daughter was
not sexually active (18.3%), and a provider did not recommend (13.1%)
were the most common reasons for parents’ nonintent to have their
daughters vaccinated.
CONCLUSIONS: Although HPV vaccine coverage rates are increasing,
they are still below target levels. Recommendations by providers to
adolescent patients and parents likely would improve vaccine uptake.
Parental education regarding disease risks and benefits of HPV vacci-
nation before exposure is needed to promote vaccine uptake.
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Quadrivalent and bivalent human pap-
illomavirus (HPV) vaccines were li-
censed for use in 2006 and 2009 re-
spectively. In 2006, the Advisory
Committee on Immunization Practices
recommended routine vaccination for
girls 11 or 12 years of age and catch-up
vaccination for girls 13 to 26 years of
age.1 Three years after that recom-
mendation, nearly one-half of girls 13
to 17 years of age in the United States
had received 1 HPV vaccine dose,
and approximately one-fourth had re-
ceived 3 doses.2 This is the first anal-
ysis to assess factors associated
with provider-verified HPV vaccina-
tion series initiation and completion
among a nationally representative
sample of adolescent girls in the
United States. The objective of this
study was to describe associations be-
tween certain sociodemographic char-
acteristics and HPV vaccination series
initiation and completion, to inform
targeted public health interventions to
increase adolescent HPV coverage.
METHODS
The National Immunization Survey
(NIS)-Teen is composed of 2 phases,
that is, (1) a random-digit-dialed tele-
phone survey of parents/guardians of
adolescents 13 to 17 years of age and
(2) a survey mailed to all vaccination
providers who were identified by the
parent and for whom consent was
granted. The NIS-Teen represents a
stratified, national, probability sample
of households in the United States, in-
cluding all 50 states, the District of Co-
lumbia, and selected local areas. It is
built on the sampling frame of tele-
phone numbers used by the NIS, which
seeks to identify vaccination rates for
children 19 to 35 months of age. Tele-
phone interviews for the 2008 and 2009
NIS-Teen surveys were conducted from
January 2008 to February 2009 and
from January 2009 to February 2010,
respectively.
All HPV vaccination coverage esti-
mates in this study were determined
on the basis of provider records. Only
adolescents with adequate provider
data (ie, those for whom sufficient vac-
cination information was obtained
from providers for determination of
vaccination status) were included in
the analysis. Details of the NIS-Teen
methods, including procedures for
combining vaccination data to pro-
duce a synthesized immunization his-
tory and weighting procedures, were
published previously.3,4 HPV vaccine
doses were considered valid if the vac-
cination date was on or after June 8,
2006, the date of licensure, and if vac-
cination occurred before or on the
date of the interview. Because the third
HPV vaccine dose is recommended to
be administered 24weeks after admin-
istration of the first dose, series com-
pletion was determined among girls
who had received 1 HPV vaccine
dose 24 weeks before the interview
date.
HPV-related questions from the house-
hold interview included parents’
knowledge of HPV disease and vaccina-
tion and receipt of a provider’s vacci-
nation recommendation. Parents who
reported that their daughters had not
received HPV vaccine were asked,
“How likely is it that [your teen] will
receive HPV shots in the next 12
months?” Parents who responded “not
too likely,” “not likely at all,” or “un-
sure” were asked, “What is the main
reason [your teen] will not receive HPV
shots in the next 12 months?” These
questions were open-ended, and re-
sponses were coded into categories;
multiple responses were allowed. So-
ciodemographic information included
the parent’s report of the adolescent’s
age, race/ethnicity, health insurance
type, and health care visits during the
past year, household income, mother’s
education level, age, and marital sta-
tus, and residential location. With the
use of collected data on household in-
come and the number of persons liv-
ing/staying in the household, income
with respect to the federal poverty
level (FPL) was determined on the ba-
sis of the 2007 and 2008 FPL thresholds
defined by the US Census Bureau. In-
surance status was categorized as (1)
private, (2) eligible for the Vaccines for
Children (VFC) program, excluding un-
insured individuals, (3) eligible for the
VFC program, uninsured individuals
only, (4) State Children’s Health Insur-
ance Program (SCHIP), (5) military, or
(6) other. VFC eligibility includes age of
18 years, American Indian/Alaskan
Native, Indian Health Service or Medic-
aid coverage, or underinsured status
and vaccination at federally qualified
health or rural health centers. SCHIP
provides health coverage for unin-
sured children in families whose in-
comes are too high for Medicaid qual-
ification but too low for purchase of
private insurance. Military insurance
included military health care, Tricare,
the Civilian Health and Medical Pro-
gram of the Uniformed Services, and
the Civilian Health and Medical Pro-
gram of the Department of Veterans
Affairs. Metropolitan statistical area
(MSA) was determined on the basis of
telephone area codes.
Data on 11- to 12-year preventive
health care visits and on facility type
and provider specialties for locations
where adolescents received vaccina-
tions were collected from question-
naires mailed to providers. Girls who
were 12 years of age at the time of
vaccine licensure andwho did not have
the opportunity to receive HPV at an
11- to 12-year preventive visit are
indicated.
Tests of association between sociode-
mographic characteristics and HPV
vaccination series initiation (receipt of
1 HPV vaccine dose) and completion
(receipt of 3 HPV vaccine doses
among individuals who initiated the se-
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ries) were performed with t tests and
logistic regression. All sociodemo-
graphic characteristics included in bi-
variate analyses were included in the
multivariate models. Because girls
who participated in the 2009 NIS-Teen
had an additional year for vaccination
since HPV vaccine licensure, com-
pared with girls who participated in
the 2008 NIS-Teen, survey year was in-
cluded in the multivariate model. State
also was included in the model, to con-
trol for differences between states in
themultiple unmeasured program fac-
tors that likely were related to the out-
come variable. Multivariate adjusted
prevalence ratios with 95% confidence
intervals (CIs) were determined for
HPV vaccination series initiation and
completion; t tests were used to test
associations between sociodemo-
graphic characteristics and parents’
intent toward vaccination, receipt of a
provider recommendation, and insur-
ance status. Differences in coverage
were considered statistically signifi-
cant at P .05. Data were analyzed by
using SAS-callable SUDAAN 9.2 (Re-
search Triangle Institute, Research Tri-
angle Park, NC), to account for the
complex sampling design of the NIS-
Teen. The NIS-Teen was approved by
the Centers for Disease Control and
Prevention institutional review board.
RESULTS
A total of 18 228 girls, 13 to 17 years of
age, had adequate provider data in the
2008 and 2009 NIS-Teen and were in-
cluded in this study. The 2008 NIS-Teen
included 30 725 completed household
interviews, for a Council of American
Survey Research Organizations re-
sponse rate of 58.7%.5 Among subjects
who completed the household survey,
58.1% had adequate provider-reported
vaccination histories.4 The 2009 NIS-
Teen included 34 976 completed
household interviews, for a Council
of American Survey Research Organi-
zations response rate of 58.0%.
TABLE 1 Characteristics of Participating Adolescent Girls Aged 13 to 17 Years
Sociodemographic Characteristic n Weighted
Proportion,
% Estimate (95% CI)
Total 18 228
Year
2008 8607 50.4 (49.2–51.6)
2009 9621 49.6 (48.4–50.8)
Age
13 y 3539 18.9 (17.9–20.0)
14 y 3816 20.1 (19.0–21.3)
15 y 3747 21.1 (20.0–22.3)
16 y 3748 20.7 (19.6–21.9)
17 y 3378 19.1 (18.0–20.3)
Race
White, non-Hispanic 12 810 60.0 (58.5–61.4)
Black, non-Hispanic 1951 15.2 (14.2–16.4)
Hispanic 2125 17.6 (16.4–18.9)
American Indian/Alaskan Native 252 0.8 (0.7–1.0)
Asian 386 2.8 (2.3–3.3)
Other 704 3.6 (3.0–4.2)
Income level
133% of FPL 3331 24.5 (23.2–25.9)
133% to322% of FPL 5740 31.4 (30.1–32.7)
322% to503% of FPL 4576 21.7 (20.7–22.7)
503% of FPL 4581 22.4 (21.3–23.6)
Mother’s education
Less than high school 1687 13.4 (12.3–14.5)
High school 3702 27.7 (26.3–29.1)
More than high school, some college 5444 26.0 (24.9–27.2)
College graduate 7395 32.9 (31.6–34.1)
Mother’s marital status
Married 13 834 74.2 (72.9–75.4)
Divorced/widowed/separated 3076 18.0 (16.9–19.1)
Never married 1173 7.8 (7.1–8.7)
Mother’s age
34 y 1339 8.5 (7.7–9.3)
35–44 y 7979 47.0 (45.6–48.5)
45 y 8910 44.5 (43.1–45.8)
MSA
Central city, MSA 6965 37.6 (36.3–39.0)
Non–central city, MSA 6903 45.8 (44.4–47.2)
Non–MSA 4360 16.6 (15.7–17.4)
Had 11- to 12-y preventive care visita
Yes 4520 23.4 (22.3–24.6)
No 5162 27.6 (26.4–28.8)
HPV vaccine not licensed when 11 or 12 y of ageb 8546 49.0 (47.6–50.4)
Insurance status
Private 12 377 63.0 (61.6–64.4)
VFC eligible, all others 3978 25.1 (23.8–26.4)
VFC eligible, uninsured only 852 6.4 (5.6–7.2)
SCHIP 486 3.7 (3.1–4.3)
Military 294 1.4 (1.1–1.6)
Other 122 0.5 (0.4–0.7)
Know of HPV
Yes 17 082 92.0 (90.9–93.0)
No 934 8.0 (7.0–9.1)
Heard of HPV vaccine
Yes 15 703 85.3 (84.1–86.4)
No 2195 14.7 (13.6–15.9)
Received provider recommendation for vaccinec
Yes 9904 53.1 (51.6–54.5)
No 7752 46.9 (45.5–48.4)
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Among subjects who completed the
household survey, 57.4% had ade-
quate provider-reported vaccination
histories.6
Sociodemographic characteristics of
the sample are presented in Table 1.
Overall, 40.5% of girls received 1
dose of HPV; the proportion was
greater in 2009 (44.1%) than in 2008
(37.0%) (Table 2). Most girls received
the first HPV vaccine dose in pediatric
offices (75%), and the second most
common location was family practice
offices (16%) (data not shown). In the
multivariate model, vaccination with
1 HPV vaccine dose was indepen-
dently associated with older adoles-
cent age, living in a high-income house-
hold, having a mother who never
married, having a younger mother,
having an 11- to 12-year preventive
visit, receiving a provider recommen-
dation for HPV vaccination, insurance
status, and facility type where the ado-
lescent received all of her vaccinations
(Table 2). Several variables were asso-
ciated with series initiation in the bi-
variate analysis but were not statisti-
cally significant in the multivariate
analysis.
Among girls who received 1 dose of
HPV vaccine, 53.3% received the com-
plete 3-dose series (Table 2). In the
multivariate analysis, completion of
the 3-dose series was independently
associated with age of 16 years,
black non-Hispanic or Hispanic race/
ethnicity, a household income of
133% to 322% of FPL, having an
older mother, parental knowledge
about HPV, and facility type where
the adolescent received all of her
vaccinations. Several variables were
associated with series completion in
the bivariate analysis but were not
statistically significant in the multi-
variate analysis.
Because receipt of a provider recom-
mendation might depend on health
care access and use, we performed lo-
gistic regression analyses excluding
provider recommendation. Indepen-
dent predictors of HPV vaccination ini-
tiation remained the same except for
the addition of living in urban versus
rural areas (P .04), having an 11- to
12-year preventive check versus being
12 years of age at the time of vaccine
licensure (P  .01), having private in-
surance versus being uninsured and
VFC-eligible (P  .01), and having pa-
rental knowledge of HPV disease (P
.01) and the vaccine (P .03). Indepen-
dent predictors of series completion
remained the same except for the ad-
dition of living in rural versus urban
areas (P  .03) and having SCHIP ver-
sus private insurance (P .05). Bivari-
ate analyses showed statistically
significant associations between
provider recommendation and race/
ethnicity, having an 11- to 12-year
preventive visit, MSA, insurance type,
and parental knowledge about HPV
and the vaccine (P  .01 for all).We
also assessed associations between
selected characteristics and insur-
ance status. Compared with other in-
surance categories, a larger propor-
tion of VFC-eligible, uninsured girls
had no parent-reported health care
visits in the past year and received
all of their vaccines at public facili-
ties (data not shown). A smaller pro-
portion of VFC-eligible, uninsured
girls received 1 other adolescent
vaccine, compared with girls in other
insurance categories.
For girls who had not received HPV
vaccine, 32.7% of parents reported
that they were very likely to have
their daughters vaccinated within
the next 12 months, 16.5% were
somewhat likely, 13.7% were not too
likely, 26.8% were not likely at all,
and 10.3% were unsure. Characteris-
tics of parents who intended to have
their daughters receive the HPV vac-
cine within the next 12 months are
presented in Fig 1. Parents who re-
sponded “very likely” or “somewhat
likely” were considered to have intent
to receive the vaccine, whereas par-
ents who responded “not too likely,”
“not likely at all,” or “unsure” were
considered to have nonintent to re-
ceive the vaccine. A significantly larger
proportion of parents who received a
provider recommendation intended to
have their daughters vaccinated. Other
statistically significant results are
noted in Fig 1. The most commonly re-
ported reasons given by parents for
not intending to have their daughters
vaccinated included lack of knowledge
about the vaccine (19.4%), vaccine is
not needed (18.8%), daughter is not
sexually active (18.3%), and did not re-
ceive a provider recommendation
(13.1%) (Table 3).
TABLE 1 Continued
Sociodemographic Characteristic n Weighted
Proportion,
% Estimate (95% CI)
Facility types for adolescent’s vaccination providers
All private facilities 9544 56.1 (54.7–57.4)
All public facilities 3315 17.8 (16.8–18.9)
All hospital facilities 1490 6.8 (6.2–7.4)
All STD/school/teen clinics or other facilities 545 2.8 (2.4–3.3)
Mixed 2411 12.0 (11.1–13.0)
Unknown 852 4.5 (3.9–5.2)
STD indicates sexually transmitted disease.
a As reported by providers.
b Girls who were older than 12 years at the time of HPV vaccine licensure (June 8, 2006) and did not have the opportunity to
receive HPV vaccine at an 11- to 12-year preventive visit.
c Parents reported whether they had received a recommendation for their daughters to receive HPV vaccinations from a
health care provider.
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TABLE 2 HPV Vaccination Coverage Among Girls 13 to 17 Years of Age, According to Sociodemographic Characteristics
Sociodemographic Characteristic 1 Dose of HPV Vaccine 3 Doses of HPV Vaccine Among Those Who
Initiated Series
Unadjusted Coverage Rate,
% Estimate (95% CI)
Prevalence Ratioa Unadjusted Coverage Rate,
% Estimate (95% CI)
Prevalence Ratioa
Total 40.5 (39.2–41.9) — 53.3 (51.1–55.6) —
Year
2008 37.0 (34.9–39.1)b 0.9 (0.8–1.0) 46.8 (43.3–0.4)b 0.8 (0.7–0.8)
2009 44.1 (42.3–46.0)c Reference 58.9 (55.9–1.7)c Reference
Age
13 y 36.0 (33.2–38.9)c Reference 45.8 (41.1–50.7)c Reference
14 y 37.1 (34.2–40.1) 1.1 (1.0–1.2) 52.1 (47.3–56.8) 1.1 (1.0–1.2)
15 y 43.9 (40.8–47.1)b 1.2 (1.1–1.4) 49.1 (44.2–54.0) 1.0 (0.9–1.2)
16 y 42.9 (39.8–46.1)b 1.3 (1.1–1.5) 59.5 (54.4–64.3)b 1.2 (1.0–1.4)
17 y 42.3 (38.9–45.7)b 1.2 (1.1–1.4) 59.0 (53.5–64.2)b 1.1 (0.9–1.4)
Race
White, non-Hispanic 39.3 (37.7–40.8)c Reference 60.4 (57.8–63.0)c Reference
Black, non-Hispanic 40.1 (36.1–44.2) 1.0 (0.9–1.1) 46.0 (39.1–53.0)b 0.9 (0.8–1.0)
Hispanic 44.5 (40.4–48.7)b 1.1 (1.0–1.2) 40.3 (34.8–46.0)b 0.8 (0.7–1.0)
American Indian/Alaskan Native 52.6 (41.4–63.5)b 1.2 (1.0–1.6) 47.1 (32.0–62.7) 1.0 (0.8–1.3)
Asian 41.1 (32.1–50.8) 1.0 (0.9–1.2) 43.9 (30.0–59.0)b 0.8 (0.6–1.2)
Other 40.9 (32.7–49.6) 0.9 (0.7–1.2) 48.5 (36.1–61.1) 0.9 (0.7–1.2)
Income level
133% of FPL 44.9 (41.6–48.3) 1.1 (0.9–1.2) 44.1 (39.0–49.4)b 1.0 (0.9–1.2)
133% to322% of FPL 34.8 (32.5–37.2)b 0.9 (0.8–1.0) 49.4 (45.2–53.6)b 0.9 (0.8–1.0)
322% to503% of FPL 39.6 (37.1–42.1)b 0.9 (0.9–1.0) 62.4 (58.5–66.2) 1.1 (1.0–1.2)
503% of FPL 44.7 (41.8–47.6)c Reference 60.0 (55.6–64.2)c Reference
Mother’s education
Less than high school 42.1 (37.7–46.6) 1.0 (0.9–1.2) 38.6 (32.4–45.2)b 0.9 (0.8–1.1)
High school 39.0 (35.9–42.2) 1.0 (0.9–1.1) 49.3 (44.0–54.7)b 0.9 (0.8–1.0)
More than high school, some college 39.9 (37.5–42.3) 1.0 (1.0–1.1) 54.0 (50.0–58.0)b 1.0 (0.9–1.1)
College graduate 41.7 (39.7–43.7)c Reference 62.0 (59.1–64.9)c Reference
Mother’s marital status
Married 39.3 (37.8–40.9)c Reference 56.2 (53.6–58.7)c Reference
Divorced/widowed/separated 41.8 (38.4–45.4) 1.1 (1.0–1.2) 48.5 (43.1–54.0)b 0.9 (0.8–1.0)
Never married 47.7 (42.2–53.2)b 1.2 (1.0–1.3) 38.1 (31.0–45.7)b 0.9 (0.7–1.1)
Mother’s age
34 y 45.6 (40.6–50.7)c Reference 36.0 (29.2–43.3)c Reference
35–44 y 39.2 (37.1–41.5)b 0.8 (0.8–0.9) 51.2 (47.5–54.8)b 1.2 (1.0–1.4)
45 y 40.9 (39.1–42.8) 0.8 (0.7–0.9) 59.2 (56.2–62.2)b 1.2 (1.0–1.5)
MSA
Urban 43.0 (40.6–45.4)c Reference 49.7 (46.0–53.3)c Reference
Suburban 41.3 (39.2–43.5) 1.0 (0.9–1.1) 55.9 (52.3–59.4)b 1.1 (1.0–1.2)
Rural 32.8 (30.4–35.2)b 0.9 (0.9–1.0) 55.4 (51.0–59.7)b 1.1 (1.0–1.2)
Had 11- to 12-y preventive care visit
Yes 48.8 (46.1–51.5)c Reference 54.6 (50.8–58.4)c Reference
No 31.2 (28.9–33.6)b 0.8 (0.7–0.9) 45.6 (41.2–50.0)b 0.9 (0.8–1.0)
HPV vaccine not licensed when 11 or 12 y of aged 41.9 (39.7–44.0)b 0.9 (0.8–1.0) 55.9 (52.4–59.3) 1.0 (0.9–1.1)
Insurance status
Private 39.0 (37.4–40.7)c Reference 57.9 (55.0–60.7)c Reference
VFC-eligible, all others 47.3 (44.2–50.5)b 1.2 (1.1–1.3) 44.9 (40.3–49.7)b 1.0 (0.9–1.1)
VFC eligible, uninsured only 23.7 (19.3–28.8)b 0.9 (0.7–1.1) 43.7 (33.7–54.2)b 1.0 (0.8–1.2)
SCHIP 52.4 (44.2–60.5)b 1.2 (1.0–1.5) 52.5 (41.3–63.4) 1.2 (1.0–1.4)
Military 35.1 (27.2–43.8) 0.8 (0.6–1.1) 57.3 (43.4–70.2) 1.0 (0.8–1.3)
Other 34.8 (21.8–50.6) 0.7 (0.4–1.2) 53.1 (31.5–73.6) 0.8 (0.5–1.3)
Know of HPV
Yes 41.9 (40.6–43.4)c Reference 55.3 (53.1–57.5)c Reference
No 25.2 (18.8–32.9)b 1.0 (0.8–1.2) 20.2 (12.7–30.7)b 0.6 (0.4–0.9)
Heard of HPV vaccine
Yes 41.8 (40.3–43.2)c Reference 55.1 (52.9–57.4)c Reference
No 33.7 (29.2–38.5)b 1.0 (0.9–1.1) 43.2 (34.3–52.5)b 0.9 (0.8–1.1)
Received provider recommendation for vaccinee
Yes 58.3 (56.5–60.2)b 2.6 (2.4–2.9) 56.9 (54.3–59.3)b 1.1 (1.0–1.2)
No 20.7 (18.9–22.7)c Reference 43.4 (38.4–48.4)c Reference
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DISCUSSION
To our knowledge, this is the first study
to examine national data on HPV vacci-
nation initiation and completion
among adolescent girls by using
provider-verified vaccination records.
Approximately 40% of girls received
1 HPV vaccine dose and, of those
girls, approximately one-half com-
pleted the 3-dose vaccination series.
Although some factors were associ-
ated with both vaccination series initi-
ation and completion, there were dif-
ferences. Race/ethnicity was not
associated with initiation; however,
black and Hispanic adolescents were
less likely to complete the series, com-
pared with white adolescents. Daugh-
ters of younger mothers were more
likely to initiate the series, whereas
daughters of older mothers were
more likely to complete it. Although ac-
cess to vaccine is provided for unin-
sured girls through the VFC program,
the lack of a medical home might con-
tribute to lower coverage rates among
VFC-eligible, uninsured girls and girls
who received all of their vaccines at
public facilities. The most common
reason for nonintent to vaccinate
one’s daughter against HPVwas lack of
knowledge about the vaccine. These
data provide information that could
help identify ways to increase HPV vac-
cine coverage in the United States.
One of the factors most strongly asso-
ciated with HPV vaccination initiation
was receipt of a provider recommen-
dation. Previous studies showed that
provider recommendations influence
parental decisions to receive HPV and
other vaccinations.7–10 Various barri-
ers at the provider level lead to missed
opportunities for vaccination, includ-
ing vaccine costs, insurance cover-
age, discomfort discussing sexuality,
and a preference to vaccinate older
adolescents.11,12 To address cost and
reimbursement barriers, the Na-
tional Vaccine Advisory Committee
recommended improving business
practices to ensure vaccine reim-
bursement, participating in vaccine-
purchasing pools, and improving
reimbursement through the VFC pro-
gram.13,14 Similar to previous studies,
we found that older adolescents were
most likely to have initiated HPV vacci-
nation.15–17 Although HPV vaccination is
recommended for girls at 11 or 12
years of age, pediatricians and family
medicine physicians aremore likely to
recommend HPV vaccination strongly
for older adolescents.12 Strong pro-
vider recommendations for HPV vacci-
nation likely would improve vaccine
uptake at the recommended age.8
Limited health care access might
hinder receipt of a provider recom-
mendation. In the model without in-
clusion of provider recommenda-
tion, a few additional variables
reflecting access to care became sig-
nificant. Therefore, increasing ac-
cess to health care, removing pro-
vider barriers, and encouraging
stronger provider recommendations
all could increase vaccine uptake.
Higher coverage rates among older
adolescent girlsmight reflectmore op-
portunities for catch-up vaccination as
adolescents grow older. The adoles-
cent platform promotes an 11- to 12-
year preventive health check for vacci-
nation and health screening.18–20 We
found that girls who underwent an 11-
to 12-year preventive check weremore
likely to have initiated vaccination than
were those without such a visit. How-
ever, there was no difference in cover-
age rates among girls who underwent
an 11- to 12-year preventive check and
those who were 12 years of age at
the time of vaccine licensure, which in-
dicates that older adolescents were
being vaccinated during subsequent
health care encounters. Approximately
50% of girls were12 years of age at
the time of HPV vaccine licensure, and
TABLE 2 Continued
Sociodemographic Characteristic 1 Dose of HPV Vaccine 3 Doses of HPV Vaccine Among Those Who
Initiated Series
Unadjusted Coverage Rate,
% Estimate (95% CI)
Prevalence Ratioa Unadjusted Coverage Rate,
% Estimate (95% CI)
Prevalence Ratioa
Facility types for adolescent’s vaccination
providers
All private facilities 44.7 (42.8–46.6)c Reference 56.2 (53.2–59.1)c Reference
All public facilities 26.5 (23.9–29.2)b 0.7 (0.6–0.8) 38.9 (33.8–44.2)b 0.8 (0.7–0.9)
All hospital facilities 44.8 (40.1–49.5) 1.0 (0.9–1.1) 53.9 (46.7–60.9) 1.0 (0.9–1.1)
All STD/school/teen clinics or other facilities 38.8 (31.0–47.2) 1.0 (0.8–1.2) 52.6 (38.9–65.9) 1.0 (0.8–1.3)
Mixed 42.4 (38.1–46.9) 1.0 (0.9–1.1) 54.6 (47.2–61.8) 0.9 (0.8–1.1)
Unknown 35.9 (29.7–42.7)b 0.9 (0.8–1.0) 47.1 (37.1–57.2) 0.9 (0.7–1.0)
STD indicates sexually transmitted disease.
a Logistic regression models were adjusted for survey year and state of residence.
b P .05.
c Reference level.
d Girls who were older than 12 years of age at the time of HPV vaccine licensure (June 8, 2006) and did not have the opportunity to receive HPV vaccine at an 11- to 12-year preventive visit.
e Parents reported whether they had received a recommendation for their daughters to receive HPV vaccinations from a health care provider.
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the 2009 NIS-Teen 1996 birth cohort is
the first full cohort that can be as-
sessed for receipt of the HPV vaccine
by the 13th birthday.21 Continued mon-
itoring of subsequent birth cohorts
will be needed to assess receipt of the
HPV vaccine by the 13th birthday. Ef-
forts to promote an 11- to 12-year pre-
ventive check and annual health care
visits, as well as use of all visits as op-
portunities for vaccination, likely will
increase HPV vaccination initiation at
the recommended age and catch-up
vaccination.
There were no differences in HPV vac-
cination initiation rates according to
racial/ethnic group; however, income
and insurance status were signifi-
cantly associated with beginning the
vaccine series. The HPV vaccination ini-
tiation rate was highest among girls
from households with the lowest in-
comes, the majority of whom were
Medicaid-eligible, had SCHIP, or were
VFC-eligible and insured; the initiation
rate was lowest among VFC-eligible,
uninsured girls. The VFC program
might be providing better access to
HPV vaccination for VFC-eligible, in-
sured girls, compared with girls with
other forms of insurance held by non–
VFC-eligible girls (ie, private, military,
or other insurance). The HPV vaccine is
one of the most expensive vaccines,
costing $130 per dose in the private
sector, and requires a 3-dose series.22
Because of costs and concerns about
reimbursement, some providers
might not stock or offer the vac-
cine,11,23 which might contribute to
lower vaccination rates among non–
VFC-eligible girls. However, HPV vacci-
nation is a covered benefit in the mili-
tary health system. Few preventive
visits, few provider recommendations,
and parent and provider attitudes
about vaccination might contribute to
lower vaccination rates for this group.
Despite VFC eligibility, uninsured girls
had the lowest vaccination initiation
rate. Lack of insurance is a known risk
factor for lack of preventive health
care among adolescents24 and low vac-
cination rates among young children.25
For uninsured individuals, health care
access is limited to public health facil-
ities or services for which they can
self-pay. With insurance, there are
more opportunities to access a medi-
cal home or usual sources of care,26,27
which have been associated with
higher vaccination rates.28 A previous
study demonstrated that VFC-eligible
children with no medical home were
less well vaccinated than VFC-eligible
children with a medical home.29
These observations might explain the
higher initiation rate among VFC-
eligible, insured girls, compared with
0 10 20 30 40 50 60 70 80
No  
Yesa
Received provider recommendaon
No
Yesa
Heard of the HPV vaccine
No
Yesa
Know of the  human papillomavirus
 45 y b
35-44 y
34  ya
Mother's age
Divorced/widowed/separated
Never marriedb
Marrieda
Mother's marital status
College  graduatea
> High school, some college
High school
<High school
Mother's educaon
>503% PVLa
322% to <503% PVLb
133% to <322% PVLb
<133% PVL
Federal poverty level
Other
Asianb
American Indian/Alaskan Nave
Hispanic,
Black, non-Hispanic
White, non-Hispanica
Race/ethnicity
17 yb
a
16 y
15 y
14 y
13 y 
Age
Frequency, %
Sociodemographic 
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FIGURE 1
Characteristics of parents who intended to have their daughters receive the HPV vaccine within the
next 12 months. Parents who responded “very likely” or “somewhat likely” were considered to have
intent to receive the vaccine, whereas parents who responded “not too likely,” “not likely at all,” or
“unsure” were considered to have nonintent to receive the vaccine. Black bars indicate 95% CIs.
a Reference level. b Significantly different from reference group estimate (P  .05). FPL indicates
poverty level.
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VFC-eligible, uninsured girls and girls
who received all of their vaccines at pub-
lic facilities. Increasing the proportion of
adolescentswith health insurance, a pri-
mary care physician, and a usual source
of care likely would improve health care
access and continuity of services.30 Im-
proved outreach to uninsured adoles-
cents and referrals to VFCproviders also
might improve vaccination coverage
among uninsured girls.
Approximately one-half of the girls who
initiated the HPV vaccination series
completed it. Reasons for low comple-
tion rates might include poor commu-
nication of the need for a 3-dose se-
ries, failure of patients and parents to
return for subsequent doses, fewer
health care visits made by adoles-
cents, and lack of a regular source of
care. Although VFC-eligible, insured
girls were more likely to initiate the
HPV vaccination series than were girls
with private insurance, fewer com-
pleted the series, compared with girls
with private insurance. Implementing
clinical practice guidelines to use re-
minder/recall systems likely would in-
crease HPV vaccination series comple-
tion rates,32 particularly for girls who
are VFC-eligible and insured or who re-
ceive vaccinations in public settings.
There were no differences in HPV vac-
cination initiation rates according to
race/ethnicity; however, we found dis-
parities in HPV vaccination completion
rates for some racial/ethnic groups.
Black and Hispanic girls were less
likely than white girls to complete the
series. Higher completion rates among
black and Hispanic girls might de-
crease disparities in cervical cancer
morbidity and mortality rates,33 which
emphasizes the need for targeted ef-
forts to increase HPV vaccination com-
pletion rates; however, additional re-
search is needed for an understanding
of the reasons for disparate comple-
tion rates for some groups.
Among unvaccinated girls, 40% of
parents reported that they were un-
likely to have their daughters vacci-
nated in the next 12 months and 10%
were unsure. The lack of knowledge
about the HPV vaccine and reports of
daughters not being sexually active
demonstrate the need for parental ed-
ucation on adolescent risks for HPV in-
fection, stressing the benefits of vacci-
nation and promoting the importance
of vaccination before exposure. As in
previous studies, few parents (1%)
reported concerns about increased
sexual activity by their daughters after
vaccination.34,35
This analysis has some limitations.
NIS-Teen is a random-digit-dialed sur-
vey and is limited to households with
landlines. Findings might not be rep-
resentative of households without
landlines and households with only
wireless telephones, which would
contribute to noncoverage bias. Ac-
cording to data from the 2009 National
Health Interview Survey, the number of
wireless-only households is increas-
ing; 25.9% of children currently live
in wireless-only households.36 Only
2.4% of children live in households
without telephone service.36 The Na-
tional Health Interview Survey, a
face-to-face household survey that
includes landline, nonlandline, and
wireless-only households, has been
assessed for sociodemographic and
health-related variables among ado-
lescents. Benchmark comparisons of
these variables for adolescents in
the NIS-Teen and the National Health
Interview Survey showed no signifi-
cant evidence of coverage bias with
adjustment of sampling weights for
noncoverage of nonlandline and
wireless-only households in the NIS-
Teen.37 Nonresponse bias might re-
main after weighting adjustments.
Provider data or vaccination histo-
ries might be incomplete. We did not
analyze other factors that might in-
fluence vaccine coverage, such as
state policies. However, state was in-
cluded in our analyses, to control for
multiple unmeasured program fac-
tors likely related to the outcome
variable. Further analyses will evalu-
ate these program factors.
CONCLUSIONS
Although HPV vaccination coverage is
increasing in the United States, it is
still below target levels. Provider rec-
ommendations are strongly associ-
ated with HPV vaccination initiation;
recommendations by providers to
their adolescent patients and parents
likely would improve vaccine uptake.
Participating in registries and imple-
menting clinical practice guidelines to
use reminder/recall systems to re-
TABLE 3 Main Reported Reasons Parents Did
Not Intend for Their 13- to 17-Year-
Old Daughters to Receive HPV
Vaccination in Next 12 Months
Reasons for Not
Intending to Receive
HPV Vaccinea
n % (95% CI)
Lack of knowledge 1089 19.4 (17.3–21.8)
Vaccination not needed
or not necessary
1189 18.8 (17.0–20.7)
Daughter not sexually
active
1171 18.3 (16.6–20.2)
Did not receive provider
recommendation
742 13.1 (11.6–14.8)
Daughter not
appropriate age
473 7.3 (6.2–8.5)
Safety concerns/adverse
effects
478 7.3 (6.3–8.5)
More information/new
vaccine
321 4.2 (3.5–5.1)
Family/parents’ decision 238 3.9 (3.2–4.8)
Already up to date 257 3.3 (2.7–4.1)
Costs 162 3.2 (2.5–4.2)
Child should make
decision
92 1.3 (0.9–2.0)
Child fearful 59 1.2 (0.8–1.9)
No doctor or doctor’s
visit not scheduled
48 1.1 (0.7–1.7)
Otherb 92 1.1 (0.9–1.3)
Handicapped/special
needs/illness
66 1.0 (0.6–1.7)
a Among adolescents whose parents responded “not too
likely,” “not likely at all,” or “unsure” to the question, “How
likely is it that [your teen] will receive HPV shots in the next
12 months?” Missing responses were excluded (6.3%).
b Other responses included vaccine effectiveness con-
cerns, college shot, do not believe in immunizations, reli-
gion/orthodox, time, vaccine not available, not a school
requirement, increased sexual activity concern, no obste-
trician/gynecologist, or daughter already sexually active.
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mind parents, patients, and vaccina-
tion providers when subsequent HPV
vaccine doses are due and to recall
persons who are overdue for vaccina-
tions likely would increase HPV vacci-
nation series completion rates.31 Pa-
rental education on disease risks
and the benefits of HPV vaccination
before exposure is needed to pro-
mote vaccine uptake. Increasing ac-
cess to health insurance and a usual
source of care and knowledge of and
linkage to the VFC program likely
would improve vaccination rates
among uninsured girls.
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IN SEARCH OF PERFECT FRUIT: A friend of mine and I play a game in which we
exchange photographs of raw food products and ask each other to guess what
it is. As she lives in Thailand, I have had to bone up on SE Asian fruits, vegetables,
and herbs. Recently, however, I was flummoxed by an unusual cross between an
apple and a pear. As reported in The Wall Street Journal (Food & Drink: Septem-
ber 7, 2011), breeders in the U.S. have for years crossed different fruit species
in search of the perfect fruit. It is usually a painstaking process. First, all the
flowers of the “mother tree”, the one which will produce the desired fruit, are
stripped of petals and pollen producing anthers. Workers then touch each of the
remaining pistils with pollen taken from a donor fruit tree. Alternatively, bees
are released into an enclosed area that contains the mother tree and a sample
of pollen from the donor fruit. The fruit produced by the mother tree is then
harvested and planted. Not until this seedling bears fruit will the breeder have
any idea whether the experiment has worked. The goal is to produce a fruit that
is sweet, hardy, and easy to grow, survive shipping, and have a long harvest
season. If the fruit meets all these criteria, farmers will be able to charge a
premium price, up to 50 cents or $1.00 a pound. However, only about 1/1000 of
the new fruits make it to market. Recent interspecies fruits that have made it to
the U.S. market include the Pluot and Aprium, both of which are crosses be-
tween plums and apricots, and the Peacharine, which is a cross between a
peach and a nectarine. Interestingly, despite the fact that these new fruits are
the product of genetic modification, they have not generated the same concern
or controversy as other genetically modified foods. This may be because every-
thing is done by hand andmimics to a large extent, what could happen in nature.
As for me, I am still disappointed that I lost the challenge. I think I will send her
a photo of a Pluerry (a cross between a plum and cherry under development)
and see how she does with that.
Noted by WVR, MD
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Dorell CG, Yankey D, Santibanez TA, Markowitz LE. Human Papillomavirus
Vaccination Series Initiation and Completion, 2008–2009. Pediatrics. 2011;128
(5):830–839
An error occurred in the article by Dorell et al titled “Human Papillomavirus
Vaccination Series Initiation and Completion, 2008–2009” published in the November
2011 issue of Pediatrics (2011;128[5]:830–839; originally published online October 7,
2011; doi:10.1542/peds.2011-0950). The error concerned rates of HPV vaccination
completion among girls. On page 831, under the methods section, second par-
agraph, lines 19–26 read: “Because the third HPV vaccine dose is recommended
to be administered 24 weeks after administration of the first dose, series com-
pletion was determined among girls who had received$1 HPV vaccine dose$24
weeks before the interview date.” However, on page 834, under Table 2 of the
results section, the vaccination coverage estimates reported in the column ‘3
doses of HPV vaccine among those who initiated series’ were not reported among
girls who had received $1 HPV vaccine dose $24 weeks before the interview
date. They were reported among girls who received $1 HPV vaccine dose any
time before the interview date and received the third HPV dose at least 6 months
after the first HPV dose. The intention of the authors was to report completion
rates among girls who received $1 HPV dose at least 6 months previous to the
date of interview to reflect completion rates among girls who had sufficient time
to complete the 3 dose HPV vaccination series. Corrected completion rates
among girls who received $1 HPV vaccine dose at least 6 months before the
interview are reported in the table. We found that HPV vaccination series com-
pletion estimates increased after limiting the analysis only to girls who had
sufficient time to complete the series before the interview date. On page 833,
under the results section, paragraph 3, lines 3–13 read: “In the multivariate
analysis, completion of the 3-dose series was independently associated with age
of 16 years, black non-Hispanic or Hispanic race/ethnicity, a household income of
133% to ,322% of FPL, having an older mother, parental knowledge about HPV,
and facility type where the adolescent received all of her vaccinations.” This
should have read, “In the multivariate analysis, completion of the 3-dose series
was independently associated with ages 14 or 16 years, Hispanic race/ethnicity, a
household income of 133% to ,322% of FPL, having an older mother, having
SCHIP, parental knowledge about HPV, receipt of a provider recommendation, and
facility type where the adolescent received all of her vaccinations.” On page 837,
under the discussion section, paragraph 6, lines 27–29 read: “Black and Hispanic
girls were less likely than white girls to complete the series.” This should have
read, “Black, Hispanic, and Asian girls were less likely than white girls to com-
plete the series; after controlling for other characteristics, these differences
were statistically significant only for Hispanic girls.” We regret the error.
doi:10.1542/peds.2012-1013
ERRATA
166 ERRATA
TABLE 2 HPV Vaccination Coverage Among Girls 13 to 17 Years of Age, According to Sociodemographic Characteristics
Sociodemographic Characteristic $1 Dose of HPV Vaccine $3 doses of HPV Vaccine Among Those Who Initiated Series
Unadjusted Coverage
Rate, % Estimate (95% CI)
Prevalence Ratioa Unadjusted Coverage
Rate, % Estimate (95% CI)
Prevalence Ratioa
Total 40.5 (39.2-41.9) ─ 64.0 (61.5-66.5) ─
Year
2008 37.0 (34.9-39.1)b 0.9 (0.8-1.0) 59.5 (55.4-63.4)b 0.9 (0.8-0.9)
2009 44.1 (42.3-46.0)c Reference 67.6 (64.4-70.6)c Reference
Age
13 y 36.0 (33.2-38.9)c Reference 56.9 (51.4-62.2)c Referent
14 y 37.1 (34.2-40.1) 1.1 (1.0-1.2) 65.0 (59.8-69.9) 1.1 (1.0-1.2)
15 y 43.9 (40.8-47.1)b 1.2 (1.1-1.4) 58.3 (52.8-63.6) 1.0 (0.9-1.1)
16 y 42.9 (39.8-46.1)b 1.3 (1.1-1.5) 69.4 (63.5-74.8)b 1.2 (1.0-1.3)
17 y 42.3 (38.9-45.7)b 1.2 (1.1-1.4) 69.4 (63.9-74.4)b 1.1 (0.9-1.3)
Race
White, non-Hispanic 39.3 (37.7-40.8)c Reference 71.2 (68.3-73.9)c Reference
Black, non-Hispanic 40.1 (36.1-44.2) 1.0 (0.9-1.1) 54.1 (46.7-61.3)b 0.9 (0.8-1.0)
Hispanic 44.5 (40.4-48.7)b 1.1 (1.0-1.2) 52.7 (46.1-59.1)b 0.9 (0.8-1.0)
American Indian/Alaskan Native 52.6 (41.4-63.5)b 1.2 (1.0-1.6) 54.2 (36.5-70.9) 1.0 (0.8-1.2)
Asian 41.1 (32.1-50.8) 1.0 (0.9-1.2) 52.4 (34.7-69.6)b 0.8 (0.6-1.2)
Other 40.9 (32.7-49.6) 0.9 (0.7-1.2) 59.4 (45.1-72.2) 0.9 (0.8-1.1)
Income level
,133% of FPL 44.9 (41.6-48.3) 1.1 (0.9-1.2) 54.0 (48.3-59.6)b 1.0 (0.8-1.1)
133% to ,322% of FPL 34.8 (32.5-37.2)b 0.9 (0.8-1.0) 59.9 (54.8-64.7)b 0.9 (0.8-1.0)
322% to ,503% of FPL 39.6 (37.1-42.1)b 0.9 (0.9-1.0) 72.7 (68.5-76.5) 1.0 (0.9-1.1)
.503% of FPL 44.7 (41.8-47.6)c Reference 71.8 (67.3-75.9)c Reference
Mother’s Education
Less than high school 42.1 (37.7-46.6) 1.0 (0.9-1.2) 47.9 (40.4-55.4)b 0.9 (0.8-1.0)
High school 39.0 (35.9-42.2) 1.0 (0.9-1.1) 60.3 (54.3-66.0)b 0.9 (0.8-1.0)
More than high school, some college 39.9 (37.5-42.3) 1.0 (1.0-1.1) 65.2 (60.8-69.4)b 1.0 (0.9-1.1)
College graduate 41.7 (39.7-43.7)c Reference 72.3 (69.2-75.2)c Reference
Mother’s marital status
Married 39.3 (37.8-40.9)c Reference 66.9 (64.1-69.5)c Reference
Divorced/widowed/separated 41.8 (38.4-45.4) 1.1 (1.0-1.2) 60.5 (53.8-66.8)b 0.9 (0.9-1.0)
Never married 47.7 (42.2-53.2)b 1.2 (1.0-1.3) 46.0 (37.9-54.2)b 0.9 (0.8-1.0)
Mother’s age
#34 y 45.6 (40.6-50.7)c Reference 47.9 (39.8-56.2)c Reference
35-44 y 39.2 (37.1-41.5)b 0.8 (0.8-0.9) 61.8 (57.6-65.8)b 1.1 (1.0-1.3)
$45 y 40.9 (39.1-42.8) 0.8 (0.7-0.9) 69.3 (66.2-72.4)b 1.2 (1.0-1.3)
MSA
Urban 43.0 (40.6-45.4)c Reference 60.2 (56.3-64.0)c Reference
Suburban 41.3 (39.2-43.5) 1.0 (0.9-1.1) 66.2 (62.1-70.1)b 1.0 (1.0-1.1)
Rural 32.8 (30.4-35.2)b 0.9 (0.9-1.0) 67.9 (63.4-72.1)b 1.1 (1.0-1.2)
Had 11- to 12-year preventive
care visit
Yes 48.8 (46.1-51.5)c Reference 64.9 (60.7-68.8)c Reference
No 31.2 (28.9-33.6)b 0.8 (0.7-0.9) 57.3 (52.2-62.2)b 1.0 (0.9-1.1)
HPV vaccine not licensed when11
or 12 y of aged
41.9 (39.7-44.0)b 0.9 (0.8-1.0) 66.3 (62.4-69.9) 1.0 (0.9-1.1)
Insurance status
Private 39.0 (37.4-40.7)c Reference 68.3 (65.1-71.4)c Reference
VFC-eligible, all others 47.3 (44.2-50.5)b 1.2 (1.1-1.3) 55.1 (50.0-60.2)b 1.0 (0.9-1.1)
VFC-eligible, uninsured only 23.7 (19.3-28.8)b 0.9 (0.7-1.1) 53.0 (41.9-63.9)b 1.0 (0.8-1.2)
SCHIP 52.4 (44.2-60.5)b 1.2 (1.0-1.5) 69.5 (57.8-79.2) 1.2 (1.1-1.4)
Military 35.1 (27.2-43.8) 0.8 (0.6-1.1) 68.9 (55.3-79.8) 1.0 (0.8-1.3)
Other 34.8 (21.8-50.6) 0.7 (0.4-1.2) 64.5 (36.6-85.1) 0.9 (0.6-1.3)
Know of HPV
Yes 41.9 (40.6-43.4)c Reference 66.2 (63.9-68.4)c Reference
No 25.2 (18.8-32.9)b 1.0 (0.8-1.2) 24.4 (14.7-37.6)b 0.6 (0.4-0.9)
Heard of the HPV vaccine
Yes 41.8 (40.3-43.2)c Reference 66.3 (63.9-68.6)c Reference
No 33.7 (29.2-38.5)b 1.0 (0.9-1.1) 50.5 (40.2-60.8)b 0.9 (0.8-1.0)
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Kiang et al. Outbreak of Osteomyelitis/Septic Arthritis Caused by Kingella
kingae Among Child Care Center Attendees. Pediatrics. 2005;116(2):e206–
e213
An error occurred in this article by Kiang et al, titled “Outbreak of Osteomyelitis/
Septic Arthritis Caused by Kingella kingae Among Child Care Center Attendees”
published in the August 2005 issue of Pediatrics (2005;116[2]:e206–e213; origi-
nally published online July 15, 2005; doi:10.1542/peds.2004-2051). On page e207,
under Intervention, lines 7–9, this reads: “a short prophylactic course of rifampin
(2 mg/kg/dose up to 600 mg per dose for adults, twice daily for 2 days)”. This
should have read: “a short prophylactic course of rifampin (10 mg/kg/dose up
to 600 mg per dose for adults, twice daily for 2 days)”.
doi:10.1542/peds.2012-1263
Hayes et al. A Multicenter Collaborative Approach to Reducing Pediatric
Codes Outside the ICU. Pediatrics. 2012;129(3):e785–e791
An error occurred in the article by Hayes et al, titled “A Multicenter Collaborative
Approach to Reducing Pediatric Codes Outside the ICU” published in the March
2012 issue of Pediatrics (2012;129[3]:e785–e791; originally published online
February 20, 2012; doi:10.1542/peds.2011-0227). Heather Richard was omitted
from the author list. The complete list of authors should read as follows:
Leslie W. Hayes, MD, Children’s Hospital of Alabama, UAB
Emily L. Dobyns, MD, FCCM, Children’s Hospital Denver
Bruno DiGiovine, MD, MPH, Wayne State University
Ann-Marie Brown, MSN, CPNP-AC/PC, CCRN, Akron Children’s Hospital
Sharon Jacobson, MBA, BSN, RN, CPHQ, Texas Children’s Hospital
TABLE 2 Continued
Sociodemographic Characteristic $1 Dose of HPV Vaccine $3 doses of HPV Vaccine Among Those Who Initiated Series
Unadjusted Coverage
Rate, % Estimate (95% CI)
Prevalence Ratioa Unadjusted Coverage
Rate, % Estimate (95% CI)
Prevalence Ratioa
Received provider recommendation
for vaccinee
Yes 58.3 (56.5-60.2)b 2.6 (2.4-2.9) 68.4 (65.8-70.9)b 1.1 (1.0-1.2)
No 20.7 (18.9-22.7)c Reference 51.5 (45.6-57.3)c Reference
Facility types for adolescent’s
vaccination providers
All private facilities 44.7 (42.8-46.6)c Reference 66.9 (63.6-70.0)c Reference
All public facilities 26.5 (23.9-29.2)b 0.7 (0.6-0.8) 49.0 (43.0-55.1)b 0.9 (0.8-1.0)
All hospital facilities 44.8 (40.1-49.5) 1.0 (0.9-1.1) 61.7 (53.6-69.2) 0.9 (0.8-1.1)
All STD/school/teen clinics or
other facilities
38.8 (31.0-47.2) 1.0 (0.8-1.2) 61.5 (44.8-75.8) 1.0 (0.8-1.2)
Mixed 42.4 (38.1-46.9) 1.0 (0.9-1.1) 68.0 (60.5-74.7) 1.0 (0.9-1.1)
Unknown 35.9 (29.7-42.7)b 0.9 (0.8-1.0) 56.8 (44.5-68.3) 0.9 (0.7-1.0)
STD indicates sexually transmitted disease.
a Logistic regression models adjusted for survey year and state of residence.
b P # .05.
c Reference level.
d Girls who were older than 12 years of age at the time of HPV vaccine licensure (June 8, 2006) and did not have the opportunity to receive HPV vaccine at an 11- to 12-year preventive visit.
e Parents reported whether they had received a recommendation for their daughters to receive HPV vaccinations from a health care provider.
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